Which states have the most prescriptions for GLP-1s?
A new study reveals how semaglutide, a breakthrough GLP-1 agonist, is transforming weight loss management in the United States, with adoption trends highlighting regional disparities and public health challenges.
The research by TrimBody M.D., based on an in-depth geographic analysis, provides valuable insights into semaglutide’s role in addressing obesity and diabetes. The study uncovers where this innovative medication is making the most impact, highlighting the intersection of prescription trends, obesity prevalence and healthcare access across the United States.
Jonathan Kinney, owner of TrimBody M.D. said, "Semaglutide represents a significant step forward in weight management. Its effectiveness in promoting meaningful weight loss has made it an essential tool for individuals struggling with obesity, particularly in states where the prevalence of obesity is highest."
Key findings:
Kentucky leads the nation with 21 prescriptions per 1,000 residents, reflecting its 36.5% obesity rate and robust healthcare access.
[Read more: Who's using GLP-1s?]
West Virginia, with the highest obesity rate (41.7%), ranks second at 18.9 prescriptions per 1,000 residents, addressing both weight loss and diabetes management.
Alaska’s adoption rate (17.5 per 1,000) stands out, despite access challenges with 14.9% of its population uninsured.
Mississippi and Louisiana round out the top five, showing high obesity rates (39.7% and 38.1%, respectively) and growing reliance on pharmaceutical solutions.
The U.S. average prescription rate is 12.5 per 1,000 residents, highlighting the urgency and innovation in regions like Kentucky and West Virginia.
With the highest prescription rate (21 per 1,000 residents), Kentucky reflects an aggressive approach to tackling obesity and diabetes. Its relatively low uninsured rate (6.2%) likely supports higher semaglutide adoption, ensuring better access to treatment.
West Virginia:
Ranking second, West Virginia’s obesity rate (41.7%) is the highest in the U.S., and its diabetes prevalence (15.2%) underscores the dual health crises addressed by semaglutide. Despite its challenges, the state’s moderate uninsured population (6%) facilitates access to this treatment.
[Read more: SoWell debuts supplement system for GLP-1 users]
Alaska:
Alaska’s high prescription growth is notable given its smaller population (0.7 million) and higher uninsured rate (14.9%). Geographic challenges, including limited access to fresh food and higher rates of sedentary lifestyles during long winters, make semaglutide a crucial tool for weight management.
Mississippi:
With an obesity rate of 39.7% and a diabetes prevalence of 14.6%, Mississippi’s adoption rate (16.1 prescriptions per 1,000 residents) highlights the importance of pharmaceutical solutions in regions with cultural dietary challenges. However, a 13% uninsured rate presents a potential barrier.
Louisiana:
Louisiana’s adoption rate (15.4 per 1,000 residents) is significant given its obesity prevalence (38.1%) and diabetes rate (14.3%). Its relatively low uninsured population (8.9%) supports easier access to semaglutide compared to neighboring states.
National context:
The USA average prescription rate (12.5 per 1,000 residents) illustrates that states like Kentucky and West Virginia are well above the national benchmark, driven by higher obesity and diabetes rates.
Conversely, states with high uninsured populations, like Alaska, show adoption despite structural barriers, suggesting significant demand for innovative healthcare solutions, the company noted.
For the full report, click here.